AbCellera Biologics Inc. (NASDAQ:ABCL) has seen 3.0 million shares traded in the last trading session. The company, currently valued at $4.89B, closed the last trade at $18.74 per share which meant it gained $1.19 on the day or 6.78% during that session. The ABCL stock price is -283.72% off its 52-week high price of $71.91 and 22.57% above the 52-week low of $14.51. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.73 million shares traded. The 3-month trading volume is 2.10 million shares.
The consensus among analysts is that AbCellera Biologics Inc. (ABCL) is a Buy stock at the moment, with a recommendation rating of 1.60. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is $0.08.
AbCellera Biologics Inc. (NASDAQ:ABCL) trade information
Sporting 6.78% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the ABCL stock price touched $18.74 or saw a rise of 1.99%. Year-to-date, AbCellera Biologics Inc. shares have moved -53.43%, while the 5-day performance has seen it change 6.60%. Over the past 30 days, the shares of AbCellera Biologics Inc. (NASDAQ:ABCL) have changed 20.05%. Short interest in the company has seen 10.49 million shares shorted with days to cover at 5.58.
Wall Street analysts have a consensus price target for the stock at $45.40, which means that the shares’ value could jump 58.72% from current levels. The projected low price target is $25.00 while the price target rests at a high of $55.00. In that case, then, we find that the current price level is -193.49% off the targeted high while a plunge would see the stock gain -33.4% from current levels.
AbCellera Biologics Inc. (ABCL) estimates and forecasts
Figures show that AbCellera Biologics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -29.97% over the past 6 months, with this year growth rate of -31.11%, compared to 7.50% for the industry. Revenue growth from the last financial year stood is estimated to be 13.40%.
4 analysts offering their estimates for the company have set an average revenue estimate of $27.64 million for the current quarter. 4 have an estimated revenue figure of $16.2 million for the next quarter concluding in Sep 2021.
AbCellera Biologics Inc. is expected to release its next earnings report on May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AbCellera Biologics Inc. (NASDAQ:ABCL)’s Major holders
Insiders own 31.55% of the company shares, while shares held by institutions stand at 47.69% with a share float percentage of 69.67%. Investors are also buoyed by the number of investors in a company, with AbCellera Biologics Inc. having a total of 129 institutions that hold shares in the company. The top two institutional holders are Capital World Investors with over 13.42 million shares worth more than $295.14 million. As of Jun 29, 2021, Capital World Investors held 4.81% of shares outstanding.
The other major institutional holder is Baker Brothers Advisors, LLC, with the holding of over 10.45 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $229.9 million and represent 3.75% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Europacific Growth Fund and Growth Fund Of America Inc. As of Jun 29, 2021, the former fund manager holds about 1.94% shares in the company for having 5.41 million shares of worth $118.99 million while later fund manager owns 3.11 million shares of worth $68.41 million as of Jun 29, 2021, which makes it owner of about 1.12% of company’s outstanding stock.